Author:
Feldman Yuval,Gauthier Rebecca,Schuler Troy
Abstract
To sell a new drug, pharmaceutical companies must discover a compound, run clinical trials to test its efficacy and safety, get it approved by regulatory bodies, produce the drug, and market it. As this process brings the drug through so many hands, there are risks of many kinds of corruption. The pharmaceutical industry has recently gone from being one of the most admired industries to being described by the majority of Americans as “dishonest, unethical, and more concerned with profits than with individual and public health.” Legal scholar Marc Rodwin suggested that the pharmaceutical industry can be viewed through the lens of institutional corruption as defined by legal scholar Lawrence Lessig, whereby widespread or systemic practices undermine the main purposes of drug therapy — healing illness, preventing medical problems, and alleviating suffering. Many drugs do serve these goals, yet a significant number of drugs churned out by pharmaceutical companies are ineffective or have dangerous side effects that could have been predicted had the companies conducted the appropriate research.
Publisher
Cambridge University Press (CUP)
Subject
Health Policy,General Medicine,Issues, ethics and legal aspects
Reference44 articles.
1. Five Un-Easy Pieces of Pharmaceutical Policy Reform
2. 37. See Kunda, , supra note 20.
3. 40. Even in the case of outside auditors, behavioral biases from familiarity over time with the client as well as wanting the client to continue to hire you lead good accountants to perform bad audits. See Brown, , supra note 36.
4. Sweeping dishonesty under the rug: How unethical actions lead to forgetting of moral rules.
5. “Credible Deterrence: The Park Doctrine and the FDA in the 21st Century,”;O'Leary;Food and Drug Law Journal
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献